SENORES — Senores Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapMomentum Trap

Annual income statement for Senores Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS
Standards:	IAS	IAS	IAS	IAS
Status:	Final	Final	Final	Final
Revenue
Total Revenue	142	353	2,145	3,983
Cost of Revenue
Gross Profit	61.4	226	1,030	2,023
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Other Operating Expenses
Total Operating Expenses	129	243	1,829	3,254
Operating Profit	12.5	111	316	729
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	11.4	124	249	706
Provision for Income Taxes
Net Income After Taxes	9.91	84.3	327	583
Minority Interest
Net Income Before Extraordinary Items
Net Income	9.91	84.3	315	586
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	9.91	84.3	315	586
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.298	2.57	9.46	16.1